Share

In the January Journal Club, we discussed the new drug J147 which targets mitochondrial dysfunction to potentially treat Alzheimer’s and other age-related diseases. We have also discussed the topic in an article last week if you wish to read about the progress being made with this drug.

Reference

Goldberg, J., Currais, A., Prior, M., Fischer, W., Chiruta, C., Ratliff, E., … & Cuezva, J. M. (2018). The mitochondrial ATP synthase is a shared drug target for aging and dementia. Aging cell.

About the author

Oliver Medvedik

Oliver Medvedik, Co-founder of Genspace citizen science laboratory in Brooklyn NY, earned his Ph.D. at Harvard Medical School in the Biomedical and Biological Sciences program. As part of his doctoral work he has used single-celled budding yeast as a model system to map the genetic pathways that underlie the processes of aging in more complex organisms, such as humans. Prior to arriving in Boston for his doctoral studies, he has lived most of his life in New York City. He obtained his bachelor’s degree in biology from Hunter College, City University of New York. Since graduating from Harvard, he has worked as a biotechnology consultant, taught molecular biology to numerous undergraduates at Harvard University and mentored two of Harvard’s teams for the international genetically engineered machines competition (IGEM) held annually at M.I.T.
Write a comment:

*

Your email address will not be published.

© 2018 - LIFE EXTENSION ADVOCACY FOUNDATION
Privacy Policy / Terms Of Use

       Powered by MMD